Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Travis B. Lewis, MD, PhD
Prevail Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hadassah Medical Center, Hadassah Ein Kerem, Dept. of Neurology, P.O. Box 12000
Jerusalem, Israel
- Shaare Zedek Medical Center, 12 Shmuel Biet Street
Jerusalem, Israel
- Sheba Medical Center, Tel Hashomer
Ramat Gan, Israel
- Tel Aviv Sourasky Medical Center, 6 Weizmann St.
Tel Aviv, Israel
- Mayo Clinic, 13400 E. Shea Boulevard
Scottsdale, Arizona, United States
- Esperanza Clinical, 25220 Hancock Avenue
Murrieta, California, United States
- Rocky Mountain Clinical Research - Cenexel - Ppds, 701 East Hampden Avenue Suite 510
Englewood, Colorado, United States
- K2 Medical Research, 101 Southhall Lane, Suite 150
Maitland, Florida, United States
- Ppd, 100 West Gore Street, Suite 202
Orlando, Florida, United States
- Northwestern University Feinberg School of Medicine, Dept. of Neurology, Parkinson'S Disease & Movement Disorders Center, 710 N. Lake Shore Drive, 11th Floor
Chicago, Illinois, United States
- Mayo Clinic, 200 First Street Sw
Rochester, Minnesota, United States
- Joan and Sanford I. Weill Department of Medicine, 525 E 68th Street
New York, New York, United States
- Mount Sinai Beth Israel, 10 Union Square East, Suite 5h
New York, New York, United States
- Hospital of the University of Pennsylvania, 330 S. 9th Street
Philadelphia, Pennsylvania, United States
- Vanderbilt University Medical Center, 1500 21st Avenue South Suite 2600
Nashville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Jan 2020
- Primary completion
- 31 Dec 2030
- Completion
- 31 Dec 2030
- Last update posted
- 13 Mar 2026
- Registered enrollment
- 32
- Registry id
- NCT04127578
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.